Drug intelligence / Profile preview

hNB001

Development stage: Preclinical
Lead developer: Harbour Antibodies
Administration: Oral, Intraperitoneal, Intracerebral

Overview

hNB001 is an investigational drug designed to alleviate migraine-related pain and anxiety. Its mechanism of action involves the inhibition of calcium-stimulating Adenylate cyclase 1 (AC1)-dependent calcitonin gene-related peptide (CGRP) signaling within the insular cortex. This targeted approach aims to modulate pathways implicated in chronic migraine and associated emotional responses.

Targets

ADCY1 (Adenylyl Cyclase Type 1)

Beyond the preview

Go deeper on hNB001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hNB001.

Explore the full profile